[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hyoung Jin Kang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100535866","phase-2-treatment-of-pediatric-very-high-risk-acute-lymphoblastic-leukemia-in-korea-100535866",false,"NCT06257394","Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea","Multi-center Clinical Trial for Optimal Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea","VHR ALL","Inclusion Criteria:\n\n* Pediatric patients diagnosed with ALL between the ages of 1 and 19 years at the time of diagnosis who meet one or more of the following conditions:\n\n  * Philadelphia chromosome-positive t(9;22)(q34;q11) or\n  * Patients with failed remission who had blast \\> 5% on bone marrow test after initial remission induction therapy or\n  * Hypodiploidy (Number of chromosomes \\< 44 (less than 44)) or\n  * E2A-HLF(Hepatic Leukemia Factor) translocation-positive or\n  * When the prognosis is judged to be poor according to NGS-MRD results among high-risk ALL patients (i) In B-ALL, the NGS-MRD(Next Generation Sequencing-Minimal Residual Disease) after consolidation therapy is 0.01% or more, and the NGS-MRD followed during interim maintenance treatment is also 0.01% or more, (ii) In T-ALL, NGS-MRD(Next Generation Sequencing-Minimal Residual Disease) is more than 0.01% after consolidation therapy\n\nExclusion Criteria:\n\n* Participants with contraindications to medications\n* When the study participant or their legal representative withdraws consent\n* Pregnant or lactating women (patients of child-bearing potential require adequate contraception during the study period)\n* Participants who are medically unsuitable to participate in this study at the discretion of the investigator Participants participating in other interventional studies other than this protocol","ALL","1 Year","19 Years",{"count":21,"type":22},74,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Very high-risk acute lymphoblastic leukemia",[28],"Acute Lymphoblastic Leukemia, Pediatric",[15,30],"NGS-MRD","RECRUITING","2025-06-04",{"date":34,"type":35},"2025-06-08","ACTUAL",{"date":37,"type":35},"2024-10-20",{"date":39,"type":22},"2034-12-31",{"name":41,"class":42},"Hyoung Jin Kang","OTHER",6,""]